SCHEMBL14737980

SCHEMBL14737980

Cn1nc2ccc(C#N)cc2c1I

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 2/20 0.41
CSNK1A1 P48729 3/20 0.35
CSNK1D P48730 3/20 0.35
CSNK1G2 P78368 3/20 0.35
GSK3B P49841 3/20 0.35
IRAK4 Q9NWZ3 4/20 0.34
CYP11B2 P19099 1/20 0.34
GAK O14976 1/20 0.33
RIPK2 O43353 1/20 0.33
COQ8A Q8NI60 1/20 0.33
NLK Q9UBE8 1/20 0.33
KDM1A O60341 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
KDR P35968 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
MTOR P42345 1/20 0.33
PRKDC P78527 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27359897 0.81 CASP3 (0.42) CASP3CSNK1A1CSNK1DCSNK1G2GSK3B
SCHEMBL13106344 0.81 CASP3 (0.51) CASP3CSNK1A1CSNK1DCSNK1G2GSK3B
SCHEMBL13106487 0.80 CASP3 (0.41) CASP3CSNK1A1CSNK1DCSNK1G2GSK3B
SCHEMBL15791953 0.75 LMNA (0.38)
SCHEMBL21265906 0.74 MEN1 (0.37) CASP3
SCHEMBL1048915 0.74 CASP3 (0.40) CASP3
SCHEMBL15792055 0.74 KDM4C (0.40)
SCHEMBL31586549 0.73 CASP3 (0.39) CASP3GSK3BCYP11B2KDM1ASLC6A4
SCHEMBL14738239 0.73 CASP3 (0.39) CASP3GSK3BCYP11B2KDM1ASLC6A4
SCHEMBL14738477 0.72 APP (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106949-A1 WRN INHIBITORS RADD PHARMACEUTICALS, INC. (US) 2025-05-22 WO disclosed
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 EP disclosed
CN-104024258-B Pyrrolopyrazine kinase inhibitors 霍夫曼-拉罗奇有限公司 2017-02-15 CN disclosed
CN-104024258-A Pyrrolopyrazine kinase inhibitors HOFFMANN LA ROCHE 2014-09-03 CN disclosed
EP-2763990-A1 PYRROLOPYRAZINE KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-08-13 EP disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US disclosed
WO-2013030138-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 WO disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK1 CASP3 2627/4885CSNK1A1 358/4885CSNK1D 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.